Fabio Del Zompo
Strasbourg, 67000, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Claudin-1 targeting suppresses tumor growth, invasion, and metastasis in patient-derived cholangiocarcinoma models.
Journal: Science translational medicine
Published: June 03, 2026
Claudin-1 is a mediator and therapeutic target in primary sclerosing cholangitis.
Journal: Journal of hepatology
Published: September 13, 2024
Impact of genetic alterations on long-term outcomes in resectable intrahepatic cholangiocarcinoma: meta-analysis.
Journal: The British journal of surgery
Published: November 26, 2023
An atlas of the human liver diurnal transcriptome and its perturbation by hepatitis C virus infection.
Journal: Nature communications
Published: October 23, 2023
Targeting the liver clock improves fibrosis by restoring TGF-β signaling.
Journal: Journal of hepatology
Published: May 05, 2023
Targeting peroxiredoxin 2 prevents hepatocarcinogenesis in metabolic liver disease models.
Journal: The Journal of clinical investigation
Published: February 02, 2023
A monoclonal antibody targeting nonjunctional claudin-1 inhibits fibrosis in patient-derived models by modulating cell plasticity.
Journal: Science translational medicine
Published: December 21, 2022
Treatment of HCC with claudin-1-specific antibodies suppresses carcinogenic signaling and reprograms the tumor microenvironment.
Journal: Journal of hepatology
Published: February 21, 2022
Showing 1-9 of 9
Last Updated: 09/26/2026